Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 01, 2015
- Source ID
- 10.1016/j.bbmt.2015.06.012
Entities
People
- Ami J. Shah
- Anders L. Fasth
- Baldeep Wirk
- Blanche P Alter
- Bruce M. Camitta
- Carmem Bonfim
- David K. Buchbinder
- H. Joachim Deeg
- Hisham Abdel-azim
- Jeanette Carreras
- Jennifer Le-Rademacher
- John E. Wagner
- Kasiani C. Myers
- Kirk R. Schultz
- Kristin M. Page
- Marc Bierings
- Mary Eapen
- Michelle A. Lee
- Minoo Battiwalla
- Mohamed Radhi
- Mouhab Ayas
- Paolo Anderlini
- Richard F. Olsson
- Robert Peter Gale
- Tim Prestidge
- Troy C. Lund
Organizations
- ARIAD Pharmaceuticals
- Actinium Pharmaceuticals (United States)
- Amgen
- Blue Cross Blue Shield Association
- Celgene
- Elevance Health, Inc.
- Fred Hutchinson Cancer Center
- GSK
- Genzyme
- HistoGenetics (United States)
- Incyte
- Kiadis Pharma (Netherlands)
- Medical College of Wisconsin
- Merck & Co.
- Miltenyi Biotec
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Marrow Donor Program
- Office of Naval Research
- Onyx Pharmaceuticals
- Osiris Therapeutics
- Otsuka (United States)
- Roche (United States)
- Sanofi-Aventis
- Seagen
- Sigma-Tau Pharmaceuticals (United States)
- St. Baldrick's Foundation
- StemCyte
- Swedish Orphan Biovitrum
- Tarix Orphan (United States)
- Terumo BCT (United States)
- University of Minnesota
- University of Utah